Pfizer Inc. Files 8-K with Financial Updates

TL;DR

Pfizer dropped its 8-K on May 1st with financial results. Check it out.

AI Summary

On May 1, 2024, Pfizer Inc. filed an 8-K report detailing its financial results and condition. The filing includes financial statements and exhibits, providing an update on the company's operational and financial performance for the period ending May 1, 2024.

Why It Matters

This filing provides investors with crucial, up-to-date information on Pfizer's financial health and operational performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) that provides standard disclosures and does not indicate any unusual or significant risks.

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• May 1, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 13-5315170 (identification_number) — I.R.S. Employer Identification No.
• 66 Hudson Boulevard East (address) — Principal executive offices
• New York, New York (address) — Principal executive offices
• 10001-2192 (zip_code) — Principal executive offices
• 212 733-2323 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.05 — ange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange

Filing Documents

• pfe-20240501.htm (8-K) — 34KB
• pfe-3312024xex99.htm (EX-99) — 581KB
• pfizerlogoa.jpg (GRAPHIC) — 38KB
• 0000078003-24-000103.txt ( ) — 876KB
• pfe-20240501.xsd (EX-101.SCH) — 3KB
• pfe-20240501_def.xml (EX-101.DEF) — 15KB
• pfe-20240501_lab.xml (EX-101.LAB) — 27KB
• pfe-20240501_pre.xml (EX-101.PRE) — 16KB
• pfe-20240501_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On May 1, 2024, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for the first quarter of 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this "Item 2.02 - Results of Operations and Financial Condition", including Exhibit 99, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Exhibit Description Exhibit 99 Press Release of Pfizer Inc. dated May 1, 2024 , reporting Pfizer's financial results for the first quarter of 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. EXHIBIT INDEX Exhibit No. Description 99 Press Release of Pfizer Inc. dated May 1, 2024, reporting Pfizer's financial results for the first quarter of 2024. 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel Dated: May 1, 2024

View Full Filing

View this 8-K filing on SEC EDGAR